drugset
drugset / Trial / NCT02811822

A Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care for the Treatment of Multiple Myeloma

NCT02811822 ↗

Phase 1 Completed 10 enrolled GlycoMimetics Incorporated
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate GMI-1271, a specific E-selectin antagonist, in multiple myeloma as adjunct to standard of care chemotherapy used to treat this disease.

Timeline

Start
2016-06
Primary completion
2019-04
Completion
2019-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Uproleselan Small molecule — —

Indications

plasma cell myeloma